B. Riley Estimates RadNet’s FY2025 Earnings (NASDAQ:RDNT)

RadNet, Inc. (NASDAQ:RDNT) – Equities researchers at B. Riley boosted their FY2025 earnings per share estimates for RadNet in a research note issued to investors on Tuesday, August 12th. B. Riley analyst Y. Zhi now anticipates that the medical research company will post earnings per share of $0.39 for the year, up from their previous estimate of $0.20. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for RadNet’s current full-year earnings is $0.56 per share.

RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Sunday, August 10th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.17 by $0.14. RadNet had a negative net margin of 0.78% and a positive return on equity of 2.41%. The business had revenue of $498.23 million during the quarter, compared to analyst estimates of $488.06 million. During the same period in the prior year, the firm posted $0.16 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis.

Other analysts have also recently issued reports about the stock. Morgan Stanley upgraded shares of RadNet to an “overweight” rating in a report on Monday. Raymond James Financial restated a “strong-buy” rating and issued a $75.00 price target (up from $66.00) on shares of RadNet in a report on Wednesday. Truist Financial set a $74.00 price target on shares of RadNet in a report on Thursday, July 10th. Finally, Wall Street Zen cut shares of RadNet from a “hold” rating to a “sell” rating in a report on Sunday, June 29th. One analyst has rated the stock with a sell rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, RadNet has an average rating of “Buy” and a consensus target price of $71.60.

RadNet Stock Up 0.5%

NASDAQ:RDNT opened at $68.75 on Thursday. RadNet has a fifty-two week low of $45.00 and a fifty-two week high of $93.65. The stock has a market capitalization of $5.29 billion, a P/E ratio of -343.73 and a beta of 1.43. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.01 and a current ratio of 2.00. The company’s 50-day simple moving average is $57.20 and its 200-day simple moving average is $55.95.

Insiders Place Their Bets

In related news, EVP Alma Gregory Sorensen sold 55,000 shares of RadNet stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $56.48, for a total transaction of $3,106,400.00. Following the completion of the sale, the executive vice president owned 1,160,509 shares of the company’s stock, valued at $65,545,548.32. The trade was a 4.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 5.60% of the company’s stock.

Institutional Trading of RadNet

A number of institutional investors and hedge funds have recently made changes to their positions in RDNT. Headlands Technologies LLC purchased a new stake in shares of RadNet in the first quarter valued at approximately $28,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of RadNet during the second quarter worth approximately $35,000. GAMMA Investing LLC increased its position in shares of RadNet by 22.3% during the first quarter. GAMMA Investing LLC now owns 1,644 shares of the medical research company’s stock worth $82,000 after purchasing an additional 300 shares in the last quarter. Family Legacy Financial Solutions LLC purchased a new stake in shares of RadNet during the second quarter worth approximately $85,000. Finally, Jones Financial Companies Lllp increased its position in shares of RadNet by 563.4% during the first quarter. Jones Financial Companies Lllp now owns 1,705 shares of the medical research company’s stock worth $85,000 after purchasing an additional 1,448 shares in the last quarter. 77.90% of the stock is currently owned by hedge funds and other institutional investors.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.